Streetbeat News

Price Targets

INTA

Oppenheimer analyst Brian Schwartz maintains an Outperform rating on Intapp (NASDAQ:INTA) and raises the price target from $42 to $54.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 12:07 pm

DIN

In the last quarter, Dine Brands Global (NYSE:DIN) received 4 somewhat bullish and 1 indifferent analyst ratings. The average 12-month price target is $77.6, representing a 5.75% decrease from the previous average of $82.33.

Portfolio Pulse from Benzinga Insights

June 14, 2023 | 12:06 pm

TFC

Credit Suisse analyst Susan Roth Katzke reiterated a Neutral rating on Truist Financial (NYSE:TFC) and maintained a $40 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 11:55 am

NTRS

Credit Suisse analyst Susan Roth Katzke reiterated an Underperform rating on Northern Trust (NASDAQ:NTRS) and maintained an $84 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 11:54 am

ORGS

Benchmark analyst Kenneth Bruce reiterated a Speculative Buy rating on Orgenesis (NASDAQ:ORGS) and maintained a $6 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 11:52 am

TSCO

Benchmark analyst John Lawrence reiterated a Buy rating on Tractor Supply (NASDAQ:TSCO) and maintained a $256 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 11:51 am

MAXN

SSNLF

Maxeon Solar Technologies has entered into an agreement with Samsung Electronics to integrate its SunPower One residential energy solution within Samsung's SmartThings connected home platform. Roth MKM analyst Philip Shen upgraded Maxeon Solar from Neutral to Buy, raising the price target from $21 to $40.

Portfolio Pulse from Nabaparna Bhattacharya

June 14, 2023 | 11:37 am

CLSD

JonesTrading analyst Sean Kim initiates coverage on Clearside Biomedical (NASDAQ:CLSD) with a Buy rating and announces a price target of $6.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 11:34 am

OCS

B of A Securities analyst Jason Gerberry initiates coverage on Oculis Holding (NASDAQ:OCS) with a Buy rating and a price target of $22.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 11:33 am

VRDN

BTIG analyst Julian Harrison initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Buy rating and announces a price target of $46.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 11:32 am